Show simple item record

dc.contributor.authorStupp, R
dc.contributor.authorTonn, J-C
dc.contributor.authorBrada, M
dc.contributor.authorPentheroudakis, G
dc.contributor.authorGrp, ESMOGW
dc.date.accessioned2018-08-21T14:53:49Z
dc.date.issued2010-05
dc.identifier5
dc.identifier.citationANNALS OF ONCOLOGY, 2010, 21 pp. v190 - v193
dc.identifier.issn0923-7534
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2368
dc.identifier.doi10.1093/annonc/mdq187
dc.format.extentv190 - v193
dc.languageeng
dc.language.isoeng
dc.publisherOXFORD UNIV PRESS
dc.titleHigh-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
dc.typeJournal Article
rioxxterms.versionofrecord10.1093/annonc/mdq187
rioxxterms.licenseref.startdate2010-05
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfANNALS OF ONCOLOGY
pubs.notesaffiliation: Stupp, R (Reprint Author), ESMO Head Off, ESMO Guidelines Working Grp, Via L Taddei 4, CH-6962 Viganello Lugano, Switzerland. Stupp, R., CHUV, Vevey, Switzerland. Stupp, R., Univ Lausanne, Lausanne, Switzerland. Stupp, R., Dept Oncol Hematol Riveria Chablais, Vevey, Switzerland. Tonn, J. -C., Univ Munich, Dept Neurosurg, Univ Klinikum Grosshadern, Munich, Germany. Brada, M., Inst Canc Res, Sutton, Surrey, England. Brada, M., Royal Marsden NHS Fdn Trust, Sutton, Surrey, England. Pentheroudakis, G., Ioannina Univ Hosp, Dept Med Oncol, Ioannina, Greece. keywords-plus: PHASE-III TRIAL; MGMT PROMOTER METHYLATION; EUROPEAN-ORGANIZATION; GLIOBLASTOMA-MULTIFORME; RECURRENT GLIOBLASTOMA; ADJUVANT TEMOZOLOMIDE; RADIATION-THERAPY; TUMOR; RADIOTHERAPY; CHEMOTHERAPY research-areas: Oncology web-of-science-categories: Oncology author-email: [email protected] funding-acknowledgement: Schering-Plough; Merck KgaA; Bristol-Myers-Squibb; Roche (Avastin); OncoMethylome Sciences; Essex (Temozolomide); Merck Serono (Cilengitide) funding-text: Dr Stupp has reported that he has been a consultant and has received honoraria from Schering-Plough, Merck KgaA, Bristol-Myers-Squibb, Roche and OncoMethylome Sciences. He has also reported that he holds stock in Pfizer; Professor Tonn has reported that he has received travel grants and speakers’ honoraria from Essex (Temozolomide), Roche (Avastin) and Merck Serono (Cilengitide); Professor Brada and Dr Pentheroudakis have reported no conflicts of interest. number-of-cited-references: 36 times-cited: 146 usage-count-last-180-days: 0 usage-count-since-2013: 16 journal-iso: Ann. Oncol. doc-delivery-number: 613HB unique-id: ISI:000278968900040 oa: gold_or_bronze da: 2018-08-21
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams/Clinical Academic Radiotherapy (Brada)
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams/Clinical Academic Radiotherapy (Brada)
pubs.volume21
pubs.embargo.termsNot known
icr.researchteamClinical Academic Radiotherapy (Brada)en_US
dc.contributor.icrauthorBrada, Michaelen


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following collection(s)

Show simple item record